Skyrizi (risankizumab) 150mg injection
Condition : New
0
From UAE
To United States
in 5-10 days
Description
Skyrizi (risankizumab) 150mg is a medication used in the treatment of moderate to severe plaque psoriasis. It is administered via subcutaneous injection and works by targeting specific proteins in the body that contribute to inflammatory conditions.
How It Works
Skyrizi contains risankizumab, a monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). IL-23 is a cytokine that plays a crucial role in the inflammatory process of psoriasis. By inhibiting IL-23, Skyrizi helps to reduce inflammation and the rapid turnover of skin cells, leading to the improvement of psoriatic plaques.Side Effects
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
- Fungal skin infections
- Itching
- Back pain
Indications
- Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Contraindications
- Serious hypersensitivity reactions to risankizumab or any of the excipients in Skyrizi.
- Active infections, particularly tuberculosis.
Price Comparison in Different Countries
Country | Price (per dose) | Reference |
---|---|---|
Pakistan | Approximately PKR 300,000 | Dawaai Pakistan |
United States | USD 16,000 | GoodRx |
United Kingdom | GBP 12,000 | NHS UK |
Canada | CAD 20,000 | MedBroadcast Canada |
Australia | AUD 22,000 | PBS Australia |
Top 5 Global Brands
- AbbVie
- Novartis
- Johnson & Johnson
- Pfizer
- Roche